NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Maverick0408,

Thermo offers a balanced view and realistic expectations. I agree with his take that 50 per month will be reached as soon as the process of funding from existing UK set aside funds becomes well known and quickly able to be deployed because costs begin to accrue from surgery with tumor tissue processing and neither Advent or NWBO are able to operate on a large deficit spend with later reimbursement. Significant funding must be available up front and used for the manufacturing stage of treatment. This must be adequately addressed by funding sources now to be able to offer any realistic hope to patients who are diagnosed late with this disease and need immediate care. This requires a structural change that takes time to adjust for and NWBO and MHRA I’m sure are fully aware which is why NICE is involved early too. Best wishes.